XML 55 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (21,155) $ (14,794) $ (10,848)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 1,033 435 312
Capital loss    1 8
Impairment of property and equipment       11
Stock-based compensation to employees, directors and non-employees consultants 2,521 4,907 3,325
Stock-based compensation to investor relations consultants 278 20 155
Decrease (increase) in other accounts receivable (303) (166) 656
Decrease (increase) in prepaid expenses (237) 269 (273)
Increase (decrease) in trade payables 1,335 (424) 455
Increase in other accounts payable and accrued expenses 1,556 958 375
Increase in deferred revenues (679) 4,284   
Increase (decrease) in advance payment from United Therapeutics (1,183) 1,576   
Decrease (increase) in interest receivable on short-term deposits (140) (395) 15
Linkage differences and interest on short and long-term restricted lease deposit (30) 35 (4)
Accretion of discount, amortization of premimum and changes in accrued interest from marketable securities 154 17   
Gain from sale of investments of available for sale marketable securities (26) (3)   
Accrued severance pay, net (11) 5 58
Net cash used in operating activities (16,887) (3,275) (5,755)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchase of property and equipment (4,309) (1,480) (962)
Investment in short-term deposits (10,202) (21,031)   
Proceeds from short-term deposits       898
Proceeds from sale of property and equipment       29
Investment in long-term deposits    (1,125) (14)
Repayment of long-term restricted deposit 869 6 13
Proceeds from sale of available for sale marketable securities 1,848 884   
Proceeds from redemption of available for sale marketable securities 529 114   
Investment in available for sale marketable securities (8,534) (8,165)   
Net cash used in investing activities (19,799) (30,797) (36)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Issuance of common stock and warrants, net of issuance costs 34,106    43,400
Exercise of warrants and options 2,198 632 3,661
Repayment of long-term loan       (24)
Net cash provided by financing activities 36,304 632 47,037
Increase (decrease) in cash and cash equivalents (382) (33,440) 41,246
Cash and cash equivalents at the beginning of the period 9,389 42,829 1,583
Cash and cash equivalents at the end of the period 9,007 9,389 42,829
Supplemental disclosure of cash flow activities:      
Cash paid during the period for: Taxes paid due to non-deductible expenses 18 14 11
Supplemental disclosure of non-cash activities:      
Purchase of property and equipment in credit 872 738 123
Issuance of shares in consideration of new facility construction 1,400 3,672   
Other receivables resulting from issuance of shares    $ 13